NasdaqGS - Delayed Quote • USD
Valneva SE (VALN)
At close: April 26 at 4:00 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 3 | 3 | 2 | 3 |
Avg. Estimate | 0.94 | -0.28 | -0.15 | -0.84 |
Low Estimate | 0.44 | -0.41 | -0.22 | -1.28 |
High Estimate | 1.28 | -0.2 | -0.08 | -0.51 |
Year Ago EPS | -0.28 | -0.26 | -1.56 | -0.15 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 4 | 4 | 4 | 4 |
Avg. Estimate | 71.99M | 42.32M | 216.94M | 242.98M |
Low Estimate | 42.21M | 31.56M | 187.22M | 228M |
High Estimate | 149.54M | 48.92M | 298.67M | 263.5M |
Year Ago Sales | 36.75M | 35.81M | 164.46M | 216.94M |
Sales Growth (year/est) | 95.90% | 18.20% | 31.90% | 12.00% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.23 | -0.25 | 0.14 | 0.12 |
EPS Actual | -0.28 | -0.26 | -0.54 | -0.49 |
Difference | -0.05 | -0.01 | -0.68 | -0.61 |
Surprise % | -21.70% | -4.00% | -485.70% | -508.30% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.94 | -0.28 | -0.15 | -0.84 |
7 Days Ago | 0.93 | -0.28 | -0.15 | -0.84 |
30 Days Ago | 0.94 | -0.28 | -0.15 | -0.77 |
60 Days Ago | 0.47 | -0.21 | 0.03 | -0.26 |
90 Days Ago | 0 | 0 | 0.02 | -0.09 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | VALN | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 435.70% | -- | -- | 6.50% |
Next Qtr. | -7.70% | -- | -- | 12.00% |
Current Year | 90.40% | -- | -- | 5.30% |
Next Year | -460.00% | -- | -- | 13.10% |
Next 5 Years (per annum) | -- | -- | -- | 11.09% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Maintains | Guggenheim: Buy to Buy | 3/22/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 3/21/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 2/29/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 2/15/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 12/4/2023 |
Maintains | HC Wainwright & Co.: Buy to Buy | 11/10/2023 |
Related Tickers
HLVX HilleVax, Inc.
12.79
+6.41%
LENZ LENZ Therapeutics, Inc.
15.72
+1.75%
ANAB AnaptysBio, Inc.
21.00
+11.29%
PEPG PepGen Inc.
11.93
+1.97%
COGT Cogent Biosciences, Inc.
6.02
+0.17%
GLUE Monte Rosa Therapeutics, Inc.
5.33
-2.20%
CALT Calliditas Therapeutics AB (publ)
19.50
+1.57%
YMAB Y-mAbs Therapeutics, Inc.
14.71
-0.88%
ZNTL Zentalis Pharmaceuticals, Inc.
11.06
+0.68%
NBTX Nanobiotix S.A.
5.74
-1.03%